Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AxoGen (GB:0HKD)
LSE:0HKD
Holding GB:0HKD?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.03Last Year’s EPS
-$0.06Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: 4.29%
|Next Earnings Date:Mar 04, 2025
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong revenue growth and strategic advancements, particularly with the BLA submission and FDA acceptance. However, challenges remain with a decrease in gross margin and continued net losses.Company Guidance
During the Q3 2024 earnings call, AxoGen provided guidance that reaffirmed their full-year revenue expectations of $182 million to $186 million, maintaining confidence in their growth trajectory. The company reported $48.6 million in revenue for the quarter, marking a 17.9% increase from the previous year, with a notable 13.7% rise in unit volume and a 4.2% price increase. Gross margin was reported at 74.9%, and the company expects to hit the higher end of their 74% to 76% gross margin range for the year. AxoGen also highlighted reaching an adjusted EBITDA of $6.5 million for the quarter, up from $2.4 million last year, and achieving positive cash flow, with cash, cash equivalents, and investments totaling $30.5 million as of September 30. Looking ahead, they emphasized their focus on completing the BLA process for Avance Nerve Graft and outlined their strategic priorities, including achieving standard of care status for their products.Strong Revenue and EBITDA Growth
Revenue for Q3 2024 was $48.6 million, an increase of approximately 18% compared to last year, while adjusted EBITDA was $6.5 million versus $2.4 million last year.
Broad-Based Revenue Performance
Revenue growth was broad-based across the portfolio, driven by improved sales productivity and commercial execution.
BLA Submission and FDA Acceptance
Completed the rolling submission of the BLA for Avance Nerve Graft and received FDA acceptance, with a review goal date of September 5, 2025.
Positive Gross Margin Trend
Gross margin was 74.9% for the quarter, with expectations to be at the high end of the 74% to 76% range for the year.
Educational Initiatives and Event Participation
Sponsored national and regional educational programs and presented data at the American Society for Surgery of the Hand, highlighting the importance of nerve repair.
---
GB:0HKD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0HKD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $15.38 | $12.67 | -17.60% |
| Aug 08, 2024 | $7.96 | $10.61 | +33.29% |
| May 02, 2024 | $6.59 | $6.01 | -8.80% |
| Mar 05, 2024 | $10.76 | $9.44 | -12.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does AxoGen (GB:0HKD) report earnings?
AxoGen (GB:0HKD) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is AxoGen (GB:0HKD) earnings time?
AxoGen (GB:0HKD) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of AxoGen stock?
The P/E ratio of AxoGen is N/A.
What is GB:0HKD EPS forecast?
GB:0HKD EPS forecast for the fiscal quarter 2024 (Q4) is $0.03.
---